Loading clinical trials...
Loading clinical trials...
ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)
Conditions
Interventions
IFN beta 1a 44 mcg TIW
Curcumin
+1 more
Locations
1
Italy
Investigational Site
Naples, Italy
Start Date
April 30, 2012
Primary Completion Date
March 31, 2016
Completion Date
March 31, 2016
Last Updated
January 22, 2019
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions